Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability of Plasmodium Vivax to Infect Mosquitoes

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2000 Nov 18

PMID 11083773

Citations 64

Authors

H Hisaeda

A W Stowers

T Tsuboi

W E Collins

J S Sattabongkot

N Suwanabun

M Torii

D C Kaslow

Affiliations

Soon will be listed here.

Abstract

Transmission-blocking vaccines are one strategy for controlling malaria, whereby sexual-stage parasites are inhibited from infecting mosquitoes by human antibodies. To evaluate whether the recently cloned Plasmodium vivax proteins Pvs25 and Pvs28 are candidates for a transmission-blocking vaccine, the molecules were expressed in yeast as secreted recombinant proteins. Mice vaccinated with these proteins adsorbed to aluminum hydroxide developed strong antibody responses against the immunogens, although for Pvs28, this response was genetically restricted. Antisera against both recombinant Pvs25 and Pvs28 recognized the corresponding molecules expressed by cultured sexual-stage parasites isolated from patients with P. vivax malaria. The development of malaria parasites in mosquitoes was completely inhibited when these antisera were ingested with the infected blood meal. Pvs25 and Pvs28, expressed in Saccharomyces cerevisiae, are as yet the only fully characterized transmission-blocking vaccine candidates against P. vivax that induce such a potent antiparasite response.

Citing Articles

Genetic polymorphisms of Plasmodium vivax transmission-blocking vaccine candidates Pvs48/45 and Pvs47 in Thailand.

Kuesap J, Suphakhonchuwong N, Eksonthi B, Huaihongthong S Malar J. 2025; 24(1):63.

PMID: 40016697 PMC: 11866859. DOI: 10.1186/s12936-025-05305-w.

Evaluation of the transmission-blocking potential of antigen Pvg37 using transgenic rodent parasites and clinical isolates.

Zhang D, Zhao Y, Liu D, Liu F, Liu P, Zhang B Front Cell Infect Microbiol. 2025; 15:1529770.

PMID: 39925376 PMC: 11802531. DOI: 10.3389/fcimb.2025.1529770.

Development and longevity of naturally acquired antibody and memory B cell responses against Plasmodium vivax infection.

Thawornpan P, Kochayoo P, Salsabila Z, Chootong P PLoS Negl Trop Dis. 2024; 18(10):e0012600.

PMID: 39446698 PMC: 11500939. DOI: 10.1371/journal.pntd.0012600.

Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase in .

Zheng W, Cheng S, Liu F, Yu X, Zhao Y, Yang F Front Cell Infect Microbiol. 2024; 14:1451063.

PMID: 39258252 PMC: 11385281. DOI: 10.3389/fcimb.2024.1451063.

A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.

Cao Y, Hayashi C, Kumar N J Infect Dis. 2024; 229(6):1894-1903.

PMID: 38408353 PMC: 11175679. DOI: 10.1093/infdis/jiae102.

References

McDonald N, Hendrickson W . A structural superfamily of growth factors containing a cystine knot motif. Cell. 1993; 73(3):421-4. DOI: 10.1016/0092-8674(93)90127-c. View

Shahabuddin M, Cociancich S, Zieler H . The Search for Novel Malaria Transmission-blocking Targets in the Mosquito Midgut. Parasitol Today. 2006; 14(12):493-7. DOI: 10.1016/s0169-4758(98)01348-9. View

Kocken C, Jansen J, Kaan A, Beckers P, Ponnudurai T, Kaslow D . Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum. Mol Biochem Parasitol. 1993; 61(1):59-68. DOI: 10.1016/0166-6851(93)90158-t. View

Kaslow D, Quakyi I, Syin C, Raum M, Keister D, Coligan J . A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature. 1988; 333(6168):74-6. DOI: 10.1038/333074a0. View

Sullivan J, Morris C, McClure H, Strobert E, Richardson B, Galland G . Plasmodium vivax infections in chimpanzees for sporozoite challenge studies in monkeys. Am J Trop Med Hyg. 1996; 55(3):344-9. DOI: 10.4269/ajtmh.1996.55.344. View

Duffy P, Kaslow D . A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun. 1997; 65(3):1109-13. PMC: 175097. DOI: 10.1128/IAI.65.3.1109-1113.1997. View

Good M, Kaslow D, MILLER L . Pathways and strategies for developing a malaria blood-stage vaccine. Annu Rev Immunol. 1998; 16:57-87. DOI: 10.1146/annurev.immunol.16.1.57. View

Harinasuta T, Suntharasamai P, Viravan C . Chloroquine-resistant falciparum malaria in Thailand. Lancet. 1965; 2(7414):657-60. DOI: 10.1016/s0140-6736(65)90395-8. View

Tsuboi T, Kaslow D, Gozar M, Tachibana M, Cao Y, Torii M . Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med. 1999; 4(12):772-82. PMC: 2230397. View

10.

Barr P, Green K, GIBSON H, Bathurst I, Quakyi I, Kaslow D . Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med. 1991; 174(5):1203-8. PMC: 2118997. DOI: 10.1084/jem.174.5.1203. View

11.

Williamson K, Criscio M, Kaslow D . Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pfs230. Mol Biochem Parasitol. 1993; 58(2):355-8. DOI: 10.1016/0166-6851(93)90058-6. View

12.

Hafalla J, Santiago M, Pasay M, Ramirez B, Gozar M, Saul A . Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Mol Biochem Parasitol. 1997; 87(1):97-9. DOI: 10.1016/s0166-6851(97)00042-x. View

13.

Kaslow D, Shiloach J . Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Biotechnology (N Y). 1994; 12(5):494-9. DOI: 10.1038/nbt0594-494. View

14.

Sharma B, Talwar K, Bhatnagar V, Kumar L, Ganguly N, Mahajan R . Recurrent anaphylaxis due to Plasmodium vivax infection. Lancet. 1979; 1(8130):1340-1. DOI: 10.1016/s0140-6736(79)91965-2. View

15.

Engers H, Godal T . Malaria vaccine development: current status. Parasitol Today. 2006; 14(2):56-64. DOI: 10.1016/s0169-4758(97)01184-8. View

16.

Snewin V, Premawansa S, Kapilananda G, Ratnayaka L, Udagama P, Mattei D . Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector. J Exp Med. 1995; 181(1):357-62. PMC: 2191816. DOI: 10.1084/jem.181.1.357. View

17.

Rieckmann K, Davis D, Hutton D . Plasmodium vivax resistance to chloroquine?. Lancet. 1989; 2(8673):1183-4. DOI: 10.1016/s0140-6736(89)91792-3. View

18.

Roberts D, Andre R . Insecticide resistance issues in vector-borne disease control. Am J Trop Med Hyg. 1994; 50(6 Suppl):21-34. DOI: 10.4269/ajtmh.1994.50.21. View

19.

Kaslow D, Quakyi I, Keister D . Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. Mol Biochem Parasitol. 1989; 32(1):101-3. DOI: 10.1016/0166-6851(89)90134-5. View

20.

Stowers A, Keister D, Muratova O, Kaslow D . A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies. Infect Immun. 2000; 68(10):5530-8. PMC: 101502. DOI: 10.1128/IAI.68.10.5530-5538.2000. View